跳转至内容
Merck
CN

GF16232295

foil, 35x47mm, thickness 0.5mm, as rolled, 99%

别名:

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
La
CAS号:
分子量:
138.91
MDL编号:
UNSPSC代码:
12352300
PubChem化学物质编号:

方案

99%

表单

foil

制造商/商品名称

Goodfellow 162-322-95

电阻率

54 μΩ-cm

尺寸 × 厚度

35 x 47 mm × 0.5 mm

沸点

3464 °C (lit.)

mp

920 °C (lit.)

密度

6.19 g/mL at 25 °C (lit.)

SMILES字符串

[La]

InChI

1S/La

InChI key

FZLIPJUXYLNCLC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

For updated SDS information please visit www.goodfellow.com.

法律信息

Product of Goodfellow

储存分类代码

4.3 - Hazardous materials which set free flammable gases upon contact with water

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
M Cozzolino et al.
The International journal of artificial organs, 30(4), 293-300 (2007-05-24)
Phosphate overload is a dramatic consequence in end-stage renal disease (ESRD) patients. Recent studies have well documented that abnormalities in mineral and bone metabolism in these patients are associated with increased cardiovascular morbidity and mortality. Elevated serum phosphate and calcium-phosphate
Tilman B Drüeke
Seminars in dialysis, 20(4), 329-332 (2007-07-20)
Controlling serum phosphorus levels in patients with renal failure is critical. The use of oral phosphate-binding agents is universal for patients with end-stage kidney disease to reduce phosphate absorption. The therapeutic goal is to reduce serum phosphorus levels without disturbing
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门